Articles

During rapid GLP-1-driven weight loss, semaglutide creates a sustained caloric deficit that elevates muscle proteolysis — STEP 1 trial data show roughly 39–40% of total weight lost is lean mass. BPC-157 counters this via GH-receptor upregulation, VEGFR2-mediated angiogenesis, and satellite-cell activation, mechanistically targeting the same catabolic pathways GLP-1 agonists leave unaddressed.

A 2025 narrative review published in Current Reviews in Musculoskeletal Medicine (Springer) concludes that BPC-157 drives robust preclinical regeneration across tendon, ligament, muscle, and bone via at least three distinct molecular pathways — yet zero human RCTs exist, and its angiogenic signaling raises unresolved oncogenic questions that performance athletes and practitioners cannot currently quantify.